secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001493152-25-027273
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine presents LPCN 2101 posters at AES meeting; no specific data disclosed
------------------------------------------------------------------------------

- Posters for LPCN 2101, a GABA A receptor PAM candidate for epilepsy, presented at AES Annual Meeting Dec 5-9, 2025.
- Poster 99.1 covers clinical PK and tolerability; Poster 99.2 covers oral toxicokinetics for women with epilepsy.
- No efficacy, safety, or numerical results included in the filing; exhibits referenced but not detailed.
- LPCN 2101 is a novel oral neuroactive steroid anti-seizure medication candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315225027273/0001493152-25-027273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315225027273/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-027273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer